Wall Street Zen upgraded Harmony Biosciences to a strong-buy rating on August 16, 2026. The move follows the company’s record-breaking second-quarter financial performance.
Quarterly revenue reached $261.28 million. This figure represents a 30.3% year-over-year increase. Earnings per share hit $1.28. This result significantly exceeded analyst estimates of $0.96.
The company’s share price has climbed nearly 28% over the past 90 days. Strong demand for WAKIX, Harmony’s flagship product, continues to support this momentum.
Management also issued updates on several late-stage neurology programs. These initiatives aim to expand the company's reach in the rare neurological disease market.